Point of Care Molecular Diagnostics Market Size By Technology [Polymerase Chain Reaction (Real Time PCR, DNA/RNA Purification), In Situ Hybridization, Chips and Microarrays, Mass Spectrometry, Sequencing, Isothermal Amplification, Others], By Infectious Diseases (MRSA, Clostridium Difficile, Vancomycin-resistant Enterococci, Carbapenem-Resistant Bacteria Testing, Flu, Respiratory Syncytial Virus, Candida, Tuberculosis and Drug-resistant TB, Meningitis, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HIV , Hepatitis C, Hepatitis B, HPV, Syphilis,), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025

Industry Trends

Point of Care Molecular Diagnostics Market Size was valued at USD 1.5 billion in 2018 and is expected to witness 9.4% CAGR from 2019 to 2025.
 

Get more details on this report - Request Free Sample PDF
 

Increasing R&D activities in drug discovery will result in development of innovative technologies that should escalate POC molecular diagnostics preference during the analysis timeframe. Research as well as academic institutes conduct R&D activities to understand reasons behind occurrence of genetic and infectious diseases. Additionally, scientists undertake several research activities that include targeted and exome sequencing allowing them to predict exact nature of the diseases. Thus, rising R&D activities will increase demand for point of care molecular diagnostics thereby, boosting the industry growth.
 

Growing awareness regarding benefits of early disease diagnosis to control occurrence of chronic diseases will fuel demand for point of care molecular diagnostic tests. Industry players engaged in manufacturing PoC molecular diagnostics are undertaking several initiatives and campaigns to educate people regarding prevention of infectious diseases. Moreover, several institutes are conducting surveys and campaigns in schools to make create awareness regarding adverse impact of several infections. Thus, growing awareness amongst people will increase demand for point of care molecular diagnostics, thereby propelling business growth. However, stringent regulatory scenario may restrain the point of care molecular diagnostics market growth to certain extent.
 

Request 15% Free Customization on this Report
 

Point of Care Molecular Diagnostics Market, By Technology

In situ hybridization (ISH) segment point of care molecular diagnostics market accounted for more than 20% revenue share in 2018 and it is expected to grow tremendously in forthcoming years. ISH technology is used in diagnosing genetic disorders, allowing direct detection of mutations in nucleic acid sequence. Advancement in ISH technology allows efficient management and diagnosis of diseases. Moreover, emerging molecular diagnostic field and availability of precise instruments utilized during in-situ hybridization process facilitates effective research that proves beneficial for the segmental growth. Additionally, ISH method allows detection and localization of DNA and RNA sequences in morphologically preserved intact cellular tissues that results in high preference. Aforementioned factors will propel the demand for ISH technique thereby, augmenting the segmental growth.
 

Chips and microarrays segment of POC molecular diagnostics market was valued more than USD 41 million in 2018 and it is anticipated to witness substantial growth in forecast period. Microarray and chips technology enable simultaneous analysis of large DNA sequences for diagnostic applications and provides high output and accurate results. Additionally, chips comprise of arrays to analyse gene expression level. For instance, the GeneChip Human Genome u133 Plus 2.0 manufactured by Thermo Fisher in 2014 consists of 1.3 million different oligonucleotides, that are used in analysing genes over 47,000 transcripts and variants. Moreover, these chips require minimum biological material for detecting mutations that rises its preference. Aforementioned factors should escalate the segmental growth.
 

Point of Care Molecular Diagnostics Market, By Infectious Diseases

Clostridium difficile segment of point of care molecular diagnostics market accounted for around than USD 37.5 million in 2018 and it is anticipated to witness tremendous growth in forthcoming future. Clostridium difficile infection is the major cause for nosocomial infectious diarrhoea. PoC molecular diagnostics possess rapid turnaround time that are potentially beneficial for decision making in various situations such as quick isolation and de-isolation of patients suffering from clostridium difficile infection. Moreover, recently developed technologically biomedical PoC tests allow real time monitoring and diagnosis of clostridium difficile. Aforementioned factors will escalate demand for point of care molecular diagnostics, thereby fostering segmental growth.
 

HIV segment of the market is anticipated to witness more than 8% growth throughout the forecast period. Detection of HIV retrovirus is based on nucleic acid testing. Point of care molecular diagnostic tests utilize microfluidic technology that emphasizes on isothermal nucleic acid amplification. Moreover, technologies such as loop-mediated isothermal amplification, recombinase polymerase amplification, loop-mediated isothermal amplification, etc will allow accurate detection of RNA targets i.e., HIV genomes. Therefore, rising availability of advanced point of care molecular diagnostics in detection of HIV will escalate the segmental growth.
 

Get more details on this report - Request Free Sample PDF
 

Point of Care Molecular Diagnostics Market, By Region

European market size is estimated to witness more than 8.5% CAGR over the forecast timeline. Increasing prevalence of infectious diseases in the region will augment demand for upgraded point of care molecular diagnostic tests. Furthermore, healthcare organizations are emphasizing on preventive care to reduce morbidity and mortality rates in Europe that further escalates the demand for PoC molecular tests. Moreover, laboratories accredited to European authorities are instructed to adopt advanced PoC diagnostic tests for accurate diagnosis that will surge its demand thereby, elevating the regional growth.
 

Asia Pacific point of care molecular diagnostics market accounted for around 19.5% revenue share in 2018. Growing patient pool suffering from infectious diseases due to poor hygiene conditions will require immediate diagnosis creating demand for PoC molecular diagnostics. Additionally, industry players and government are taking several initiatives for increasing access to technologically advanced point of care molecular diagnostics. Above mentioned factors will positively impact the industry growth in forthcoming future.
 

Get more details on this report - Request Free Sample PDF
 

Competitive Market Share

Some of the notable players operating in the PoC molecular diagnostics market are Abaxis, Roche, Abbott, Danaher, BioMerieux, Sysmex, Bio-Rad Laboratories, OraSure Technologies and Bayer. These market players are implementing strategies such as collaborations, geographical expansions, product launches, mergers and acquisitions. These strategies enable companies to capture higher market share and sustain industry competition.
 

Recent industry developments:

• In February 2019, Bio-Rad Laboratories product QXDx AutoDG ddPCR system received FDA clearance. This product is used for monitoring patient’s molecular response to treatment. Thus, FDA approved products will enable company to gain competitive advantage.
   
• In April 2017, Roche launched cobas Liat PCR system that is used for sensitive diagnosis of clostridium difficile. These products enable in delivering accurate and timely diagnosis of this infection. Thus, product launches will enable company to capture higher market share.
   

Point of Care (PoC) Molecular Diagnostics Industry Background

Point of care molecular diagnostics industry can be traced back to late 1900’s. In 1980, clinicians faced troubles in diagnosing health problems and discovering solutions for the same. After extensive research, in 1987, the U.S. Department of Energy established 1^st human genome project to protect humans from mutagenic effects caused by radiation. Later, as the technology progressed, industry players took several efforts to develop effective point of care molecular diagnostics. In 1991, Myriad company developed newest cutting-edge technology by using genetic information to enhance healthcare. In 2003, Northrop Grumman cooperated with Cepheid to provide diagnostic services in biohazardous situations i.e., anthrax outbreak in the U.S. Later several industry players developed biomedical point of care technologies that could deliver results in less time and with maximum accuracy. PoC molecular diagnostics market is in developing stage in emerging countries such as China and India as these countries have huge population suffering from infectious diseases. In developed economies, PoC molecular diagnostics industry is matured since, the technology has penetrated the market. Therefore, industry players focus on creating differentiation in product to sustain in the point of care molecular diagnostics industry.